Wells Fargo maintains Outperform, while lifting the valuation range from $61 to $64 up to $63 to $68.
Wells Fargo analyst Jim Birchenough maintained an Underperform rating on shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), with a valuation range of $5.
In a research report issued yesterday, Wells Fargo analyst Jim Birchenough reiterated an Underperform rating on shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), with a valuation range of $5.
Oncology therapy company Celgene Corporation (NASDAQ:CELG) announced a definitive agreement on July 14 to acquire Receptos Inc (NASDAQ: RCPT). Under the terms of …
BMO Capital analyst Jim Birchenough weighed in with a few insights on bluebird bio Inc (NASDAQ:BLUE) after the company announced that the NIH’s Recombinant DNA …
BMO Capital analyst Jim Birchenough came out today with a research report on Regeneron Pharmaceutals Inc (NASDAQ:REGN), reiterating a Market Perform rating on the stock with a …
On May 19, Intercept Pharmaceuticals Inc (NASDAQ:ICPT) announced plans for an international Phase 3 trial of OCA in patients with NASH. Although this …
